Kymera Therapeutics CEO sells 30,000 shares

Q: How many KYMR shares did Nello Mainolfi sell, and at what prices?

Nello Mainolfi sold 30,000 KYMR common shares on October 1, 2026. The six reported lots were 3,525 shares at a weighted-average $111.44, 5,506 at $112.42, 4,876 at $113.24, 7,601 at $114.43, 8,230 at $115.40, and 262 at $116.12. Each price is the weighted average for that lot.

Q: What were the terms of Nello Mainolfi’s KYMR option exercise?

He exercised options for 30,000 shares at $2.08 per share on October 1, 2026. The options were fully vested and exercisable and had an expiration date of November 13, 2029; the reported option position after the exercise was 60,000 shares.

The reported transactions were made under a Rule 10b5-1 plan adopted March 24, 2026.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Kymera Therapeutics, Inc. (KYMR) Chief Executive Officer Nello Mainolfi exercised options for 30,000 shares on October 1, 2026, at $2.08 per share, acquiring 30,000 common shares. He sold 30,000 common shares in six transactions; the reported weighted-average prices for the lots were $111.44, $112.42, $113.24, $114.43, $115.40, and $116.12. The option position was 60,000 shares after exercise. The transactions were made under a Rule 10b5-1 plan adopted March 24, 2026.

Insider Trade Summary 10b5-1

Exercise and Sale: 30,000 shares ($3.35M approx. pre-tax spread)

Exercise and Sale 8 txns

Insider Mainolfi Nello

Role Chief Executive Officer

Sold 30,000 shs ($3.41M)

Approx. gross sale proceeds $3.41M

Approx. exercise cost $62K

Approx. pre-tax spread $3.35M

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy) ^{F1, F8}	30,000	$0.00	$0.00
Exercise	Common Stock ^F1	30,000	$2.08	$62K
Sale	Common Stock ^{F1, F2}	3,525	$111.44	$393K
Sale	Common Stock ^{F1, F3}	5,506	$112.42	$619K
Sale	Common Stock ^{F1, F4}	4,876	$113.24	$552K
Sale	Common Stock ^{F1, F5}	7,601	$114.43	$870K
Sale	Common Stock ^{F1, F6}	8,230	$115.40	$950K
Sale	Common Stock ^{F1, F7}	262	$116.12	$30K

Holdings After Transaction: Stock Option (Right to Buy) — 60,000 contracts (Direct); Common Stock — 666,568 shares (Direct)

Footnotes (8)

F1. These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person.
F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.93 to $111.90, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.97 to $112.92 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.95 to $113.88 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.94 to $114.91 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.94 to $115.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.09 to $116.16 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8. The shares underlying this stock option are fully vested and exercisable.

Key Figures

Options exercised: 30,000 shares Exercise price: $2.08 per share Common shares acquired: 30,000 shares +4 more

7 metrics

Options exercised 30,000 shares October 1, 2026

Exercise price $2.08 per share Options exercised October 1, 2026

Common shares acquired 30,000 shares Upon exercise on October 1, 2026

Common shares sold 30,000 shares Six transactions on October 1, 2026

Option position after exercise 60,000 shares Reported after the October 1, 2026 exercise

Option expiration date November 13, 2029 Stock option

Rule 10b5-1 plan adoption date March 24, 2026 Plan governing the reported transactions

Key Terms

Rule 10b5-1 trading plan, weighted average price, Stock Option (Right to Buy), fully vested and exercisable

4 terms

Rule 10b5-1 trading plan regulatory

"pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy)"

fully vested and exercisable financial

"shares underlying this stock option are fully vested and exercisable"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many KYMR shares did Nello Mainolfi sell, and at what prices?

Nello Mainolfi sold 30,000 KYMR common shares on October 1, 2026. The six reported lots were 3,525 shares at a weighted-average $111.44, 5,506 at $112.42, 4,876 at $113.24, 7,601 at $114.43, 8,230 at $115.40, and 262 at $116.12. Each price is the weighted average for that lot.

What were the terms of Nello Mainolfi’s KYMR option exercise?

He exercised options for 30,000 shares at $2.08 per share on October 1, 2026. The options were fully vested and exercisable and had an expiration date of November 13, 2029; the reported option position after the exercise was 60,000 shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 10/01/2026 - 05:20 PM Accepted by SEC EDGAR 10/01/2026 - 05:20 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mainolfi Nello

(Last)

(First)

(Middle)

C/O KYMERA THERAPEUTICS, INC.

500 NORTH BEACON STREET, 4TH FLOOR

(Street)

WATERTOWN

MASSACHUSETTS

02472

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kymera Therapeutics, Inc. [ KYMR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/01/2026		M⁽¹⁾		30,000	A	$2.08	696,568	D
Common Stock	10/01/2026		S⁽¹⁾		3,525	D	$111.44⁽²⁾	693,043	D
Common Stock	10/01/2026		S⁽¹⁾		5,506	D	$112.42⁽³⁾	687,537	D
Common Stock	10/01/2026		S⁽¹⁾		4,876	D	$113.24⁽⁴⁾	682,661	D
Common Stock	10/01/2026		S⁽¹⁾		7,601	D	$114.43⁽⁵⁾	675,060	D
Common Stock	10/01/2026		S⁽¹⁾		8,230	D	$115.4⁽⁶⁾	666,830	D
Common Stock	10/01/2026		S⁽¹⁾		262	D	$116.12⁽⁷⁾	666,568	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$2.08	10/01/2026		M⁽¹⁾			30,000	⁽⁸⁾	11/13/2029	Common Stock	30,000	$0	60,000	D

Explanation of Responses:

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.93 to $111.90, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.97 to $112.92 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.95 to $113.88 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.94 to $114.91 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.94 to $115.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.09 to $116.16 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

8. The shares underlying this stock option are fully vested and exercisable.

	/s/ Bruce Jacobs, as Attorney-in-Fact	10/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR